Janux Therapeutics, Inc. (JANX)
16.87
+0.62
(+3.85%)
USD |
NASDAQ |
Sep 17, 16:00
16.87
0.00 (0.00%)
After-Hours: 18:48
Janux Therapeutics Enterprise Value : 42.29M for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 42.29M |
| September 15, 2026 | 54.20M |
| September 14, 2026 | 107.34M |
| September 11, 2026 | 94.51M |
| September 10, 2026 | 129.94M |
| September 09, 2026 | 230.71M |
| September 08, 2026 | 274.08M |
| September 04, 2026 | 286.30M |
| September 03, 2026 | 259.42M |
| September 02, 2026 | 253.31M |
| September 01, 2026 | 203.84M |
| August 31, 2026 | 162.92M |
| August 28, 2026 | 151.31M |
| August 27, 2026 | 197.12M |
| August 26, 2026 | 203.84M |
| August 25, 2026 | 191.01M |
| August 24, 2026 | 186.13M |
| August 21, 2026 | 112.22M |
| August 20, 2026 | 105.50M |
| August 19, 2026 | 120.16M |
| August 18, 2026 | 85.96M |
| August 17, 2026 | 43.21M |
| August 14, 2026 | 34.65M |
| August 13, 2026 | 27.32M |
| August 12, 2026 | 68.25M |
| Date | Value |
|---|---|
| August 11, 2026 | 59.09M |
| August 10, 2026 | 52.37M |
| August 07, 2026 | 18.16M |
| August 06, 2026 | 33.43M |
| August 05, 2026 | 27.32M |
| August 04, 2026 | 24.88M |
| August 03, 2026 | -14.21M |
| July 31, 2026 | -23.37M |
| July 30, 2026 | 1.672M |
| July 29, 2026 | -36.20M |
| July 28, 2026 | -33.75M |
| July 27, 2026 | 1.062M |
| July 24, 2026 | -13.60M |
| July 23, 2026 | 10.22M |
| July 22, 2026 | 4.115M |
| July 21, 2026 | 43.21M |
| July 20, 2026 | 30.38M |
| July 17, 2026 | 43.21M |
| July 16, 2026 | 17.55M |
| July 15, 2026 | 29.16M |
| July 14, 2026 | 13.89M |
| July 13, 2026 | 35.88M |
| July 10, 2026 | 51.76M |
| July 09, 2026 | 73.13M |
| July 08, 2026 | 67.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 571.92M |
| Amgen, Inc. | 246.77B |
| Anika Therapeutics, Inc. | 265.74M |
| BioCryst Pharmaceuticals, Inc. | 2.635B |
| Imunon, Inc. | 7.560M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.97M |
| Revenue (Quarterly) | 10.27M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.3491 |
| Gross Profit Margin (Quarterly) | 95.49% |
| Profit Margin (Quarterly) | -214.0% |
| Earnings Yield | -9.74% |
| Normalized Earnings Yield | -9.744 |